Brief Title: 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

• Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
* Patients with histologically confirmed metastatic urothelial carcinoma with extrapelvic nodal and/or visceral sites of disease (including lung, liver, bone, or soft tissue)

- * At least 3 lesions assessable by FDG PET/CT according to RECIST and PERCIST guidelines where applicable, that are determined suspicious for metastasis by an MSKCC attending radiologist or nuclear medicine physician.

- * Karnofsky performance status ≥50% (or ECOG/WHO ≤2)

- * Participant is ≥18 years of age

- * Patient must be able to understand and is willing to sign a written informed consent document
Exclusion Criteria:
* Patients with pelvic node-only metastatic disease. If the patient has lymph node only disease, at least one PET-assessable node must be located outside of the pelvis

- * Patients with bone only disease

- * Unable to lie flat, still, or to tolerate a PET scan

- * Patient undergoing active treatment for non-urothelial malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized.

- * Patients on a therapeutic clinical trial

- * Patients undergoing active surveillance with a known history of non-urothelial malignancies

- * Women who are pregnant. All women of childbearing potential must have a documented negative pregnancy test.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Gopakumar Iyer

Role: Principal Investigator

Affiliation: Memorial Sloan Kettering Cancer Center

Overall Contact

Name: Gopakumar Iyer, MD, Michael Morris, MD

Phone: 646-888-4737, 646-422-4469

Email: iyerg@mskcc.org

LOCATION